Abeona Therapeutics
ABEO
37 hedge funds and large institutions have $37.9M invested in Abeona Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
78% more capital invested
Capital invested by funds: $21.2M → $37.9M (+$16.6M)
12% more funds holding
Funds holding: 33 → 37 (+4)
7.15% more ownership
Funds ownership: 42.5% → 49.64% (+7.1%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.8M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$1.74M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$739K |
| 5 |
Citigroup
New York
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$341K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$93.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$87.1K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$67.2K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$62.1K |
ABEO Hedge Fund Activity: Q2 2023 in Review
37 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2023, worth a combined $37.9M — up 78% from $21.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ABEO positions and 5 closed out — a net gain of 4 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.8M. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $341K sold.
- 37 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2023, up from 33 in Q1 2023.
- Funds reported $37.9M of Abeona Therapeutics stock for Q2 2023, up 78% quarter-over-quarter.
- 9 funds opened new Abeona Therapeutics positions in Q2 2023 and 5 closed out, a net change of +4 holders.
- The largest Abeona Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $1.8M added.
- The largest Abeona Therapeutics seller in Q2 2023 was ExodusPoint Capital Management, an estimated $341K sold.
Based on aggregated 13F filings for Q2 2023.